tiprankstipranks
Advertisement
Advertisement

BMRN Stock Latest News

BioMarin announces new research from studies of Voxzogo
The FlyBioMarin announces new research from studies of Voxzogo
3h ago
BMRN
Snap upgraded, Pinterest downgrade: Wall Street’s top analyst calls
PremiumThe Fly
Snap upgraded, Pinterest downgrade: Wall Street’s top analyst calls
6d ago
IT
MU
BioMarin Completes Amicus Acquisition, Expands Rare Disease Portfolio
PremiumCompany Announcements
BioMarin Completes Amicus Acquisition, Expands Rare Disease Portfolio
6d ago
8K
BMRN
BioMarin completes acquisition of Amicus Therapeutics
PremiumThe Fly
BioMarin completes acquisition of Amicus Therapeutics
6d ago
BMRN
FOLD
BioMarin resumed with an Overweight at Morgan Stanley
PremiumThe Fly
BioMarin resumed with an Overweight at Morgan Stanley
6d ago
BMRN
FOLD
BMRN Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsBMRN Upcoming Earnings Report: What to Expect?
6d ago
BMRN
BioMarin set to acquire Amicus after regulatory clearance
Premium
Company Announcements
BioMarin set to acquire Amicus after regulatory clearance
10d ago
8K
BMRN
BioMarin’s BMN 333 Takes On Vosoritide in High Stakes Achondroplasia Trial
Premium
Company Announcements
BioMarin’s BMN 333 Takes On Vosoritide in High Stakes Achondroplasia Trial
10d ago
BMRN
BioMarin appoints Ian Clark as Chair of the Board
PremiumThe Fly
BioMarin appoints Ian Clark as Chair of the Board
12d ago
BMRN
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
PremiumCompany Announcements
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
2M ago
BMRN
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
PremiumRatings
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
2M ago
BMRN
Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness
PremiumThe Fly
Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness
2M ago
BMRN
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
PremiumCompany AnnouncementsBioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
2M ago
8K
BMRN
BioMarin discontinues enrollment in some Phase 2 Voxzogo trials
Premium
The Fly
BioMarin discontinues enrollment in some Phase 2 Voxzogo trials
2M ago
BMRN
BioMarin’s Voxzogo shows impact in pediatric achondroplasia
Premium
The Fly
BioMarin’s Voxzogo shows impact in pediatric achondroplasia
2M ago
BMRN
BioMarin: Strategic Amicus Acquisition Supports Buy Rating Despite Voxzogo Assumption Reset
PremiumRatings
BioMarin: Strategic Amicus Acquisition Supports Buy Rating Despite Voxzogo Assumption Reset
2M ago
BMRN
BioMarin price target lowered to $85 from $97 at BofA
PremiumThe Fly
BioMarin price target lowered to $85 from $97 at BofA
2M ago
BMRN
FOLD
BioMarin price target raised to $105 from $80 at Barclays
PremiumThe Fly
BioMarin price target raised to $105 from $80 at Barclays
2M ago
BMRN
BioMarin price target raised to $105 from $80 at Barclays
PremiumThe Fly
BioMarin price target raised to $105 from $80 at Barclays
2M ago
BMRN
BioMarin announces U.S FDA approved sBLA for Palynziq
PremiumThe FlyBioMarin announces U.S FDA approved sBLA for Palynziq
2M ago
BMRN
BioMarin price target raised to $104 from $98 at Canaccord
Premium
The Fly
BioMarin price target raised to $104 from $98 at Canaccord
2M ago
BMRN
FOLD
BioMarin price target raised to $94 from $90 at Bernstein
Premium
The Fly
BioMarin price target raised to $94 from $90 at Bernstein
2M ago
BMRN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >